Culture Biosciences has introduced a new solution for biotech and cellular agriculture teams: the Stratyx 250, a mobile, cloud-based bioreactor system designed to streamline process development. This new bioreactor promises to cut down on development time and costs, improve scalability, and simplify bioprocess monitoring and control, offering key benefits for growing companies in the cellular agriculture space.
The Stratyx 250 is tailored to meet the specific needs of biotech companies, particularly those working on cellular agriculture, where efficient scaling and optimization are critical. Traditionally, bioreactor systems require extensive manual oversight, specialized expertise, and complex infrastructure to process vast amounts of experimental data.
The Stratyx 250 addresses these challenges by combining automation, AI-driven data analysis, and cloud-based control, enabling remote monitoring and real-time adjustments. This means that teams can make data-driven decisions faster and more efficiently, improving the consistency and reproducibility of experiments.
Efficiency and scalability
One of the standout features of the Stratyx 250 is its mobility. Designed to be easily moved within lab spaces, this bioreactor system is particularly beneficial for smaller teams or labs with limited infrastructure. Its plug-and-play design removes the need for significant space or complex integration, offering a simple solution that can be set up quickly, making it especially useful for startups in the cellular agriculture sector.
Compared to traditional benchtop bioreactors, it reduces the cost per run by 16% and cuts down on maintenance costs by eliminating the need for cleaning between runs, thanks to its single-use bioreactor technology. With these improvements, biotech teams can achieve faster development cycles—up to 25% quicker—and see a 30% improvement in scale-up success, all of which are crucial for companies in cellular agriculture looking to move from small-scale experiments to larger production volumes.
The Stratyx 250’s cloud-based platform allows teams to remotely monitor and control bioreactor parameters using Culture Biosciences’ Culture Console software. This means teams can optimize their processes and make adjustments in real-time without being physically present in the lab, simplifying complex bioprocesses and reducing the need for highly specialized staff.
Supporting scale-up with flexible technology
For companies looking to scale operations, the Stratyx 250 also integrates with Cytiva’s 250mL consumable, which features Xcellerex X-Platform technology. This integration provides a smoother path from small-scale experimentation to large-scale production by replicating conditions found in larger bioreactors, minimizing resource use, and ensuring that teams can scale more effectively.
The Stratyx 250 is now available for demonstrations at Culture Biosciences’ South San Francisco facility. The company is also offering an Early Adopter Program, which includes special pricing and free consumables for select customers who want to integrate the system into their workflows.
Chris Williams, CEO of Culture Biosciences, explains, “The shift toward cloud-powered, modular bioprocessing is accelerating in the biotech and biopharma sectors, and the Stratyx 250 was built to meet these needs. It offers a flexible, cost-effective solution for teams that require faster development cycles and scalability.”
